Drug Topics, August 19th, 2002
Generic name
Fulvestrant
Proprietary name/manufacturer
Faslodex / AstraZeneca
FDA-approved indication
Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy
Pharmacology
Fulvestrant is an estrogen receptor antagonist without known agonist effects. Fulvestrant competes with endogenous estrogen for estrogen receptor binding and downregulates the estrogen receptor protein in human breast cancer cells. The relative binding affinity of fulvestrant is 89% that of estradiol, while that of tamoxifen is 2.5%...
HighBeam Research, Free Preview: 'P & T portfolio'... Full Membership required for unlimited access. Free 7-day trial.
Subscribers: HighBeam content is only available to HighBeam subscribers. Click the link above for more information.
